Medicus Sciences Acquisition (MSAC) 10-Q/A20 Jan 222021 Q3 Quarterly report (amended)Financial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2021	Nov. 04, 2021
Document Information [Line Items]
Document Type	10-Q/A
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Entity File Number	001-40068
Entity Registrant Name	MEDICUS SCIENCES ACQUISITION CORP.
Entity Incorporation, State or Country Code	KY
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	152 West 57th Street, Floor 20
Entity Address, City or Town	New York,
Entity Address State Or Province	NY
Entity Address, Postal Zip Code	10019
City Area Code	212
Local Phone Number	259-8400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	true
Entity Central Index Key	0001836517
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	true
Amendment Description	Amendment No. 1
Class A ordinary shares
Document Information [Line Items]
Title of 12(b) Security	Class A ordinary shares, $0.0001 par value
Trading Symbol	MSAC
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		9,292,000
Class B ordinary shares
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		2,323,000
Redeemable Warrants Exercisable For Class Common Stock
Document Information [Line Items]
Title of 12(b) Security	Redeemable warrants, each warrant exercisable for one Class A ordinary share for $11.50 per share
Trading Symbol	MSACW
Security Exchange Name	NASDAQ

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current Assets:
Cash	$ 1,584,979	$ 2,000
Prepaid expenses	200,322
Due from Sponsor	118
Deferred offering costs		127,186
Total current assets	1,785,419	129,186
Investments held in Trust Account	92,007,046
Derivative asset - forward purchase agreement	9,406
Total Assets	93,801,871	129,186
Current liabilities:
Accrued offering costs and expenses	67,137	23,969
Private placement proceeds received in advance		2,000
Due to related party	25,714
Promissory note - related party		84,285
Total current liabilities	92,851	110,254
Deferred underwriting commissions	2,300,000
Derivative liability	5,787,091
Total liabilities	8,179,942	110,254
Commitments and Contingencies
Class A ordinary shares subject to possible redemption, 9,200,000 and no shares at redemption value of $10.00 per share as of September 30, 2021 and December 31, 2020, respectively	92,000,000
Shareholders' Equity (Deficit):
Additional paid-in capital		24,768
Accumulated Deficit	(6,378,312)	(6,068)
Total shareholders' equity (deficit)	(6,378,071)	18,932
Total Liabilities, Redeemable Ordinary Shares and Shareholders' Equity (Deficit)	93,801,871	129,186
Class A ordinary shares
Shareholders' Equity (Deficit):
Ordinary shares	9
Class B ordinary shares
Shareholders' Equity (Deficit):
Ordinary shares	$ 232	$ 232

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical)	Sep. 30, 2021$ / sharesshares
Preference shares, par value, (per share) \| $ / shares	$ 0.0001
Preference shares, shares authorized	1,000,000
Preference shares, shares issued	0
Preference shares, shares outstanding	0
Class A ordinary shares
Ordinary shares, par value, (per share) \| $ / shares	$ 0.0001
Ordinary shares, shares authorized	200,000,000
Ordinary shares, shares issued	92,000
Ordinary shares, shares outstanding	92,000
Ordinary shares, shares subject to possible redemption, issued (in shares)	9,200,000
Class A ordinary shares subject to possible redemption
Ordinary shares, par value, (per share) \| $ / shares	$ 10
Temporary Equity, Par or Stated Value Per Share \| $ / shares	$ 0.0001
Class A Ordinary shares subject to possible redemption outstanding	9,200,000
Ordinary shares, shares subject to possible redemption, issued (in shares)	9,200,000
Class B ordinary shares
Ordinary shares, par value, (per share) \| $ / shares	$ 0.0001
Ordinary shares, shares authorized	20,000,000
Ordinary shares, shares issued	2,323,000
Ordinary shares, shares outstanding	2,323,000
Ordinary shares, shares subject to possible redemption, issued (in shares)	2,323,000

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended	9 Months Ended
CONDENSED STATEMENTS OF OPERATIONS - USD ($)	Sep. 30, 2021	Sep. 30, 2021
Formation and operating costs	$ 168,309	$ 470,104
Loss from Operations	(168,309)	(470,104)
Other income (expenses):
Interest earned on investments held in Trust Account	1,168	7,046
Offering costs allocated to warrants		(205,898)
Change in fair value of warrant liability and derivative asset - forward purchase agreement, net	2,426,517	2,831,668
Total other income, net	2,427,685	2,632,816
Net income	$ 2,259,376	$ 2,162,712
Class A ordinary shares
Other income (expenses):
Net income per ordinary share (Basic)	$ 0.19	$ 0.22
Weighted average shares outstanding (basic)	9,292,000	7,658,242
Net income per ordinary share (Diluted)	$ 0.19	$ 0.22
Weighted average shares outstanding (Diluted)	9,292,000	7,658,242
Class B ordinary shares
Other income (expenses):
Net income per ordinary share (Basic)	$ 0.19	$ 0.22
Weighted average shares outstanding (basic)	2,323,000	2,269,529
Net income per ordinary share (Diluted)	$ 0.19	$ 0.22
Weighted average shares outstanding (Diluted)	2,323,000	2,269,529

CONDENSED STATEMENTS OF CHANGES

CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)	Class A ordinary sharesCommon Stock	Class B ordinary sharesCommon Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at the beginning at Dec. 31, 2020		$ 232	$ 24,768	$ (6,068)	$ 18,932
Balance at the beginning (in shares) at Dec. 31, 2020		2,323,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of representative shares	$ 9		911		920
Issuance of representative shares (in shares)	92,000
Accretion to redemption value for Class A ordinary shares subject to possible redemption			(25,679)	(8,534,957)	(8,560,636)
Net income (loss)				1,446,358	1,446,358
Balance at the end at Mar. 31, 2021	$ 9	$ 232		(7,094,667)	(7,094,426)
Balance at the end (in shares) at Mar. 31, 2021	92,000	2,323,000
Balance at the beginning at Dec. 31, 2020		$ 232	$ 24,768	(6,068)	18,932
Balance at the beginning (in shares) at Dec. 31, 2020		2,323,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)					2,162,712
Balance at the end at Sep. 30, 2021	$ 9	$ 232		(6,378,312)	(6,378,071)
Balance at the end (in shares) at Sep. 30, 2021	92,000	2,323,000
Balance at the beginning at Mar. 31, 2021	$ 9	$ 232		(7,094,667)	(7,094,426)
Balance at the beginning (in shares) at Mar. 31, 2021	92,000	2,323,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)				(1,543,021)	(1,543,021)
Balance at the end at Jun. 30, 2021	$ 9	$ 232		(8,637,688)	(8,637,447)
Balance at the end (in shares) at Jun. 30, 2021	92,000	2,323,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)				2,259,376	2,259,376
Balance at the end at Sep. 30, 2021	$ 9	$ 232		$ (6,378,312)	$ (6,378,071)
Balance at the end (in shares) at Sep. 30, 2021	92,000	2,323,000

CONDENSED STATEMENT OF CASH FLO

CONDENSED STATEMENT OF CASH FLOWS	9 Months Ended
CONDENSED STATEMENT OF CASH FLOWS	Sep. 30, 2021USD ($)
Cash Flows from Operating Activities:
Net income	$ 2,162,712
Adjustments to reconcile net income to net cash used in operating activities:
Interest earned on investments held in Trust Account	(7,046)
Change in fair value of warrant liability and derivative asset - forward purchase agreement, net	(2,831,668)
Offering costs allocated to warrants	205,898
Changes in operating assets and liabilities:
Prepaid expenses	(200,322)
Due from Sponsor	(118)
Due to related party	25,714
Accrued expenses	(2,463)
Net cash used in operating activities	(647,293)
Cash Flows from Investing Activities:
Investment of cash in Trust Account	(92,000,000)
Net cash used in investing activities	(92,000,000)
Cash Flows from Financing Activities:
Proceeds from initial public offering	92,000,000
Proceeds from private placement	4,218,000
Payment of underwriter discount in cash at IPO	(1,840,000)
Proceeds from promissory note - related party	215,715
Payment of deferred offering costs	(363,443)
Net cash provided by financing activities	94,230,272
Net change in cash	1,582,979
Cash, beginning of period	2,000
Cash, end of the period	1,584,979
Supplemental disclosure of cash flow information:
Offering costs included in accrued offering costs and expenses	24,600
Issuance of representative shares	920
Deferred underwriting commissions payable charged to additional paid in capital	2,300,000
Repayment of promissory note - related party through reduction in proceeds from private placement	$ 300,000

Organization and Business Opera

Organization and Business Operations	9 Months Ended
Organization and Business Operations	Sep. 30, 2021
Organization and Business Operations
Organization and Business Operations	Note 1 — Organization and Business Operations Medicus Sciences Acquisition Corp. (the “Company”) is a newly organized blank check company incorporated in the Cayman Islands on November 26, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (“Business Combination”). The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of September 30, 2021, the Company had not commenced any operations. All activity through September 30, 2021 relates to the Company’s formation and the Initial Public Offering (“IPO”), which is described below, and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the IPO. The registration statement for the Company’s IPO was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on February 12, 2021 (the “Effective Date”). Simultaneously with the closing of the IPO, the Company consummated the sale of 5,022,222 private placement warrants (the “Private Placement Warrants”) to the Sponsor and Maxim Partners LLC (3,642,222 Private Placement Warrants to the Sponsor and 1,380,000 to Maxim Partners LLC) at a price of $0.90 per Private Placement Warrant, generating total gross proceeds of $4,520,000. Also, simultaneously with the closing of the IPO, the Company issued to designees of Maxim Partners LLC 92,000 shares of non-redeemable Class A ordinary shares (the “representative shares”). The Company estimated the fair value of the stock to be $920 based upon the price of the founder shares issued to the Sponsor. The representative shares were treated as underwriters’ compensation and charged directly to shareholders’ equity. Transaction costs amounted to $4,677,181 consisting of $1,840,000 of underwriting discount, $2,300,000 of deferred underwriting discount, the fair value of the representative shares of $920 and $537,181 of other cash offering costs. Following the closing of the IPO on February 18, 2021, $92,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was placed in a Trust Account and invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions of Rule 2a-7 under the Investment Company Act which only in direct U.S. government treasury obligations. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay the income taxes, if any, the Company’s amended and restated memorandum and articles of association will provide that the proceeds from the IPO and the sale of the private placement warrants held in the Trust Account will not be released from the Trust Account (1) to the Company, until the completion of the initial Business Combination, or (2) to the public shareholders, until the earliest of (a) the completion of the initial Business Combination, and then only in connection with those Class A ordinary shares that such shareholders properly elected to redeem, subject to the limitations, (b) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the Company’s amended and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to provide holders of the Company’s Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the Company’s public shares if the Company does not complete the initial Business Combination within 24 months from the closing of the IPO (the “Combination Period”), or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares, and (c) the redemption of the public shares if the Company has not consummated the initial Business Combination within the Combination Period. Public shareholders who redeem their Class A ordinary shares in connection with a shareholder vote described in clause (b) in the preceding sentence shall not be entitled to funds from the Trust Account upon the subsequent completion of an initial Business Combination or liquidation if the Company has not consummated an initial Business Combination within the Combination Period, with respect to such Class A ordinary shares so redeemed. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the public shareholders. Risks and Uncertainties On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus (the “COVID-19 outbreak”). In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve. The impact of the COVID-19 outbreak on the Company’s financial position will depend on future developments, including the duration and spread of the outbreak and related advisories and restrictions. These developments and the impact of the COVID-19 outbreak on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s financial position may be materially adversely affected. Additionally, the Company’s ability to complete an initial Business Combination may be materially adversely affected due to significant governmental measures being implemented to contain the COVID-19 outbreak or treat its impact, including travel restrictions, the shutdown of businesses and quarantines, among others, which may limit the Company’s ability to have meetings with potential investors or affect the ability of a potential target company’s personnel, vendors and service providers to negotiate and consummate an initial Business Combination in a timely manner. The Company’s ability to consummate an initial Business Combination may also be dependent on the ability to raise additional equity and debt financing, which may be impacted by the COVID-19 outbreak and the resulting market downturn. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Restatement of Previously Issue

Restatement of Previously Issued Financial Statements	9 Months Ended
Restatement of Previously Issued Financial Statements	Sep. 30, 2021
Restatement of Previously Issued Financial Statements
Restatement of Previously Issued Financial Statements	Note 2 — Restatement of Previously Issued Financial Statements In connection with the preparation of the Company’s financial statements as of September 30, 2021, management determined it should restate its presentation of its Class A ordinary shares subject to redemption. The Company previously determined that temporary equity should consist of the Class A ordinary shares subject to possible redemption at their redemption value of $10.00 per Class A ordinary share while also taking into consideration its charter’s requirement that a redemption cannot result in net tangible assets being less than $5,000,001. Upon review of its financial statements for the quarterly period ended September 30, 2021, the Company reevaluated the classification of a portion of the Class A ordinary shares in permanent equity and determined that all Class A ordinary shares issued in the IPO can be redeemed or become redeemable subject to the occurrence of future events considered outside the Company’s control under ASC 480-10-S99. Therefore, management concluded that the Class A ordinary shares subject to possible redemption should be classified as temporary equity in its entirety. This resulted in an increase to temporary equity, with the offset recorded to additional paid-in capital (to the extent available), accumulated deficit and Class A ordinary shares. The accompanying statements of changes in shareholders' equity and cash flows no longer present the change in redeemable shares to align with the presentation of all redeemable Class A ordinary shares as temporary equity. In connection with the change in presentation for the Class A ordinary shares subject to redemption, the Company also revised its earnings per share calculation to allocate net income (loss) evenly to Class A and Class B ordinary shares. This presentation shows both classes of ordinary shares share pro rata in the income (loss) of the Company. The impact of the restatement on the Company’s financial statements is reflected in the following table. As As Reported Adjustment Restated Balance Sheet as of March 31, 2021 (per Form 10-Q filed on May 24, 2021) Ordinary shares subject to possible redemption ($) $ 79,905,570 $ 12,094,430 $ 92,000,000 Shareholders’ equity (deficit) Class A ordinary shares, $0.0001 par value 130 (121) 9 Additional paid-in capital 3,559,352 (3,559,352) — Accumulated Deficit 1,440,290 (8,534,957) (7,094,667) Total shareholders’ equity (deficit) $ 5,000,004 $ (12,094,430) $ (7,094,426) Shares subject to possible redemption 7,990,557 1,209,443 9,200,000 Statement of Operations for the Three Months Ended March 31, 2021 (per Form 10-Q filed on May 24, 2021) Weighted average shares outstanding, Redeemable Class A ordinary shares 9,292,000 (5,058,978) 4,233,022 Basic and diluted net income per share, Redeemable Class A ordinary shares $ — $ 0.23 $ 0.23 Weighted average shares outstanding, Non-redeemable Class A and Class B ordinary shares 2,158,033 — 2,158,033 Basic and diluted net income per shares, Non-redeemable Class A and Class B ordinary shares $ 0.67 $ (0.44) $ 0.23 Statement of Changes in Shareholders’ Equity as of March 31, 2021 (per Form 10-Q filed on May 24, 2021) Sale of 9,200,000 Units on February 18, 2021 through IPO, including over-allotment, net of fair value of warrant liability and offering costs $ 83,439,364 $ (83,439,364) $ — Change in Class A ordinary shares subject to possible redemption (79,905,570) 79,905,570 — Remeasurement of Class A ordinary shares subject to possible redemption against additional paid-in capital and accumulated deficit — (8,560,636) (8,560,636) Statement of Cash Flows as of March 31, 2021 (per Form 10-Q filed on May 24, 2021) Initial value of shares subject to possible redemption $ 75,523,530 $ 16,476,470 $ 92,000,000 Change in value of Class A ordinary shares subject to possible redemption $ 4,382,040 $ (4,382,040) $ — Balance Sheet as of June 30, 2021 (per Form 10-Q filed on August 5, 2021) Ordinary shares subject to possible redemption ($) $ 78,362,550 $ 13,637,450 $ 92,000,000 Shareholders’ equity (deficit) Class A ordinary shares, $0.0001 par value 146 (137) 9 Additional paid-in capitaT 5,102,357 (5,102,357) — Accumulated Deficit (102,731) (8,534,957) (8,637,688) Total shareholders’ equity (deficit) $ 5,000,004 $ (13,637,451) $ (8,637,447) Shares subject to possible redemption 7,836,255 1,363,745 9,200,000 Statement of Operations for the Three Months Ended June 30, 2021 (per Form 10-Q filed on August 5, 2021) Weighted average shares outstanding, Redeemable Class A ordinary shares 9,292,000 — 9,292,000 Basic and diluted net income per share, Redeemable Class A ordinary shares $ — $ (0.13) $ (0.13) Weighted average shares outstanding, Non-redeemable Class A and Class B ordinary shares 2,323,000 — 2,323,000 Basic and diluted net income per shares, Non-redeemable Class A and Class B ordinary shares $ (0.05) $ (0.08) $ (0.13) Statement of Operations for the Six Months Ended June 30, 2021 (per Form 10-Q filed on August 5, 2021) Weighted average shares outstanding, Redeemable Class A ordinary shares 9,292,000 (2,515,514) 6,776,486 Basic and diluted net income per share, Redeemable Class A ordinary shares $ — $ (0.01) $ (0.01) Weighted average shares outstanding, Non-redeemable Class A and Class B ordinary shares 2,242,000 (1,028) 2,240,972 Basic and diluted net income per shares, Non-redeemable Class A and Class B ordinary shares $ (0.67) $ 0.66 $ (0.01) Statement of Changes in Shareholders’ Equity as of June 30, 2021 (per Form 10-Q filed on August 5, 2021) Remeasurement in Class A ordinary shares subject to possible redemption $ 1,543,021 $ (1,543,021) $ — Statement of Cash Flows as of June 30, 2021 (per Form 10-Q filed on August 5, 2021) Initial value of shares subject to possible redemption $ 75,523,535 $ 16,476,465 $ 92,000,000 Change in value of Class A ordinary shares subject to possible redemption $ 2,839,015 $ (2,839,015) $ —

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
Significant Accounting Policies	Sep. 30, 2021
Significant Accounting Policies
Significant Accounting Policies	Note 3 — Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by US GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included Annual Report on Form 10-K filed by the Company with the SEC on March 31, 2021. Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available and, accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents in its operating account as of September 30, 2021 and December 31, 2020. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of September 30, 2021, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Warrant Liabilities and Derivative Assets - Forward Purchase Agreement The Company accounts for the Warrants and its Forward Purchase Agreement (“FPA”) as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the Warrants and FPA and the applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the Warrants and FPA are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the Warrants and FPA are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance of the Warrants and execution of the FPA and as of each subsequent quarterly period end date while the Warrants and FPA are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, such warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, such warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability-classified warrants are recognized as a non-cash gain or loss on the statements of operations. The Company accounts for the Warrants and FPA in accordance with ASC 815-40 under which the Warrants and FPA do not meet the criteria for equity classification and must be recorded as derivatives. The fair value of the Public Warrants has been estimated using its quoted market price as of September 30, 2021. The fair value of the Private Placement Warrants has been estimated using the modified Black-Scholes-Merton model. The fair value of the FPA has been estimated using an adjusted net assets method. See Note 10 for further discussion of the fair value measurement. The Company evaluated the Public Warrants, contingent rights, Private Placement Warrants and FPA (as defined in Note 8) in accordance with ASC 815-40, “Derivatives and Hedging — Contracts in Entity’s Own Equity”, and concluded that a provision in the Warrant Agreement related to certain tender or exchange offers precludes the Warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as derivative liabilities on the Condensed Balance Sheet and measured at fair value at inception (on the date of the IPO) and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in the Condensed Statement of Operations in the period of change. Offering Costs Associated with the Initial Public Offering The Company complies with the requirements of the ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. The Company allocates the offering costs between ordinary share and warrants using a relative fair value method, pursuant to which the offering costs allocated to the public warrants will be expensed immediately. Accordingly, as of September 30, 2021, allocated offering costs in the aggregate of $205,898 have been charged to operations. Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, Class A ordinary shares is classified as shareholders’ equity. Most of the Company’s Class A ordinary shares feature certain redemption rights that is considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, 9,200,000 Class A ordinary shares subject to possible redemption were presented as temporary equity, outside of the shareholders’ equity section of the Company’s unaudited condensed balance sheet. Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes (“ASC 740”). ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for the financial statements’ recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. The Company’s management does not expect the total amount of unrecognized tax benefits will materially change over the next twelve months. The provision for income taxes was deemed to be de minimis for the three and nine months ended September 30, 2021. Net Income (Loss) Per Ordinary Share Net income (loss) per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the IPO and Private Placement to purchase an aggregate of 8,088,889 shares of the Company’s Class A Ordinary Shares in the calculation of diluted income (loss) per share, since their exercise is contingent. Accretion associated with the redeemable shares of Class A ordinary share is excluded from earnings per share as the redemption value approximates fair value. As a result, diluted income per ordinary share is the same as basic income per ordinary share. For the three months ended September 30, 2021 Class A C lass B Allocation of net income including ordinary shares subject to possible redemption $ 1,807,501 $ 451,875 Weighted Average Ordinary Shares outstanding 9,292,000 2,323,000 Basic and Diluted net income per share $ 0.19 $ 0.19 For the nine months ended September 30, 2021 Class A C lass B Allocation of net income including ordinary shares subject to possible redemption $ 1,668,307 $ 494,405 Weighted Average Ordinary Shares outstanding 7,658,242 2,269,529 Basic and Diluted net income per share $ 0.22 $ 0.22 Fair Value of Financial Instruments The Company follows the guidance in ASC 820, “Fair Value Measurement,” for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment. Level 2 — Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means. Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement. As of September 30, 2021 and December 31, 2020, the carrying values of cash, prepaid expenses, and current liabilities approximate their fair values due to the short-term nature of the instruments. See Note 10 for additional information on assets and liabilities measured at fair value. Recent Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

Initial Public Offering ("IPO")

Initial Public Offering ("IPO")	9 Months Ended
Initial Public Offering ("IPO")	Sep. 30, 2021
Initial Public Offering ("IPO")
Initial Public Offering ("IPO")	Note 4 — Initial Public Offering (“IPO”) On February 18, 2021, the Company sold 9,200,000 Units, at a purchase price of $10.00 per Unit, which included the full exercise by the underwriters of the over-allotment option to purchase an additional 1,200,000 Units. Each Unit consists of one Class A ordinary share, one-ninth of one two All of the 9,200,000 Class A ordinary shares sold as part of the Units in the IPO contain a redemption feature which allows for the redemption of such public shares in connection with the Company’s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s certificate of incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary share subject to redemption to be classified outside of permanent equity. Given that the Class A ordinary share was issued with other freestanding instruments (i.e., public warrants), the initial carrying value of Class A ordinary share classified as temporary equity is the allocated proceeds based on the guidance in ASC 470-20. The Class A ordinary share is subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Immediately upon the closing of the IPO, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable Class A ordinary shares resulted in charges against additional paid-in capital and accumulated deficit. As of September 30, 2021, the redeemable Class A ordinary shares reflected on the balance sheet are reconciled in the following table: Gross proceeds from public issuance $ 92,000,000 Less: Proceeds allocated to public warrants (4,089,353) Class A ordinary shares issuance costs (4,471,283) Plus: Accretion of carrying value to redemption value 8,560,636 Contingently redeemable Class A ordinary share $ 92,000,000

Private Placement

Private Placement	9 Months Ended
Private Placement	Sep. 30, 2021
Private Placement.
Private Placement	Note 5 — Private Placement Simultaneously with the closing of the IPO, the Sponsor and Maxim Partners LLC purchased an aggregate of 5,022,222 Private Placement Warrants (3,642,222 Private Placement Warrants by the Sponsor and 1,380,000 by Maxim Partners LLC) at a price of $0.90 per Private Placement Warrant, for an aggregate purchase price of $4,520,000, in a private placement (the “Private Placement”). These Private Placement Warrants are also exercisable to purchase one Class A ordinary share at $11.50 per share and are identical to the warrants being sold as part of the Units in the IPO, subject to certain limited exceptions. If the Company does not consummate an initial Business Combination within the Combination Period, the proceeds from the sale of the private placement warrants held in the Trust Account will be used to fund the redemption of the public shares (subject to the requirements of applicable law) and the private placement warrants will expire worthless. The private placement warrants (i) will be non-redeemable and exercisable on a cashless basis so long as they are held by the Sponsor, Maxim Partners LLC or their permitted transferees. If the private placement warrants are held by holders other than the Sponsor, Maxim Partners LLC or their permitted transferees, the private placement warrants will be redeemable by the Company and exercisable by the holders on the same basis as the warrants included in the Units being sold in the IPO.

Related Party Transactions

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2021
Related Party Transactions
Related Party Transactions	Note 6 — Related Party Transactions Founder Shares The Sponsor paid $25,000 of expenses on behalf of the Company in exchange for 2,323,000 shares of the Company’s Class B ordinary shares, or approximately $0.01 per share, in connection with formation. The founder shares included an aggregate of up to 303,000 shares subject to forfeiture if the over-allotment option is not exercised by the underwriters in full. On February 18, 2021, the underwriter exercised the over-allotment option in full, hence, the 303,000 founder shares are no longer subject to forfeiture. The Sponsor and each member of the Company’s management team have agreed to waive their rights to liquidating distributions from the Trust Account with respect to any founder shares they hold if the Company fails to consummate an initial Business Combination within the Combination Period (although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to consummate an initial Business Combination within the Combination Period). The Sponsor has agreed not to transfer, assign or sell (i) any of their founder shares until the earliest of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the public shareholders having the right to exchange their ordinary shares for cash, securities or other property, and (ii) any of their private placement warrants and Class A ordinary shares issued upon conversion or exercise thereof until 30 days after the completion of the initial Business Combination. Promissory Note — Related Party On December 7, 2020, the Company issued an unsecured promissory note to the Sponsor, pursuant to which the Company may borrow up to an aggregate principal amount of $300,000 to be used for a portion of the expenses of the IPO. This loan is non-interest bearing, unsecured and due at the earlier of June 30, 2021 or the closing of the IPO. The outstanding balance of $300,000 under the promissory note was repaid through a reduction in the private placement proceeds received from the Sponsor at the closing of the initial public offering and private placement on February 18, 2021. As of September 30, 2021, there was no remaining amount outstanding. The Company no longer has the ability to borrow under this arrangement. Due to Related Party The balance of $25,714 represents the amount accrued for the administrative support services provided by Sponsor commencing on the effective date of the IPO to September 30, 2021. Working Capital Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $2,000,000 of such Working Capital Loans may be convertible upon consummation of the Business Combination into additional private placement warrant at a price of $0.90 per warrant. The warrants would be identical to the private placement warrants, including as to exercise price, exercisability and exercise period. As of September 30, 2021 and December 31, 2020, there were no amounts outstanding under the Working Capital Loans. Administrative Service Fee Commencing on the effective date of the IPO, the Company has agreed to pay an affiliate of the Company’s Sponsor a total of $10,000 per month for office space, utilities and secretarial and administrative support. Upon completion of the Company’s Business Combination or its liquidation, the Company will cease paying these monthly fees. For the three and nine months ended September 30, 2021, the Company has incurred $55,714 and $30,000 of administrative service fee, respectively, of which $25,714 is accrued and presented as due to related party on the accompanying unaudited condensed balance sheet as of September 30, 2021. Forward Purchase Agreement Upon closing of the IPO, The Company entered into an FPA, as amended with funds affiliated with Altium Capital Management, LP and Sio Capital Management, LLC (collectively, the “Forward Purchasers”). Pursuant to the FPA, the Forward Purchasers have agreed to purchase an aggregate of up to $16,000,000 of units (the “Forward Purchase Units”, the Class A ordinary shares and warrants constituting the Forward Purchase Units referred to as the “Forward Purchase Shares” and “Forward Purchase Warrants,” respectively, and collectively with the Class A ordinary shares underlying the Forward Purchase Warrants, the “Forward Purchase Securities”), which will have a purchase price of $10.00 per Forward Purchase Unit and consist of one Class A ordinary share and one-third of one warrant. The purchase of the 1,600,000 Forward Purchase Units will take place in a private placement substantially concurrently with the closing of the initial Business Combination. The Forward Purchasers have no obligation to purchase the Forward Purchase Units unless proceeds from sale of the Forward Purchase Units are necessary to enable the Company to complete the initial Business Combination. In that event, the Forward Purchasers’ obligation to purchase the Forward Purchase Units is limited to the purchase amount necessary to provide the Company with sufficient funds to consummate the initial Business Combination and to pay related fees and expenses, after first applying amounts available to the Company from the Trust Account (after giving effect to any redemptions of public shares) and any other equity financing source obtained by the Company for such purpose at or prior to the consummation of the initial Business Combination, plus any additional amounts mutually agreed and the target company to be retained by the post-business combination company for working capital or other purposes. In the event less than the full amount of the Forward Purchase Units is purchased, the Forward Purchasers will participate in the forward purchase proportionally. In addition, to the extent that the Forward Purchasers offer a bridge loan or any other form of financing to a target company in connection with a proposed initial business combination between the Company and that target company, the Forward Purchasers’ forward purchase obligation shall be reduced by the amount of such loan or other financing. The Forward Purchasers’ obligation to purchase the Forward Purchase Units may not be transferred to any other parties. The proceeds of any sales of Forward Purchase Units will not be deposited in the Trust Account. The terms of the Forward Purchase Shares and Forward Purchase Warrants, respectively, will be identical to the terms of the Class A ordinary shares and the Redeemable Warrants included in the Units being issued in the IPO except that they will be subject to certain transfer restrictions and have certain registration rights. The Company has initially classified the FPA as a derivative. This financial instrument is subject to re-measurement at each balance sheet date. With each such re-measurement, the FPA asset or liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations. As such, the Company recorded a $521,597 derivate liability related to the FPA as of February 18, 2021. At June 30, 2021 and September 30, 2021, the re-measurement of the derivative associated with the FPA resulted in a derivative asset, and accordingly, for the six months ended June 30, 2021 and the three months ended September 30, 2021, the Company recorded a change in the fair value of the derivate instrument associated with the FPA as an increase of $529,744 and an increase of $1,259 on the statement of operations, respectively, resulting in a derivative asset - FPA of $9,406 as of September 30, 2021 on the balance sheet. Derivate liability - forward purchase agreement at February 18, 2021 $ (521,597) Change in fair value of derivate instrument related to forward purchase agreement 529,744 Derivative asset - forward purchase agreement at June 30, 2021 $ 8,147 Change in fair value of derivate instrument related to forward purchase agreement 1,259 Derivative asset - forward purchase agreement at September 30, 2021 $ 9,406

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2021
Commitments and Contingencies.
Commitments and Contingencies	Note 7 — Commitments and Contingencies Registration Rights The holders of the founder shares, Private Placement Warrants, Forward Purchase Securities and warrants that may be issued upon conversion of Working Capital Loans will have registration rights to require the Company to register a sale of any of its securities held by them pursuant to a registration rights agreement signed on February 12, 2021. These holders will be entitled to make up to three demands, excluding short form registration demands, that the Company registers such securities for sale under the Securities Act. In addition, these holders will have “piggy-back” registration rights to include their securities in other registration statements filed by the Company. Underwriting Agreement The underwriters were paid a cash underwriting discount of 2.0% of the gross proceeds of the IPO, or $1,840,000 in the aggregate, upon closing of the IPO and the over-allotment option. Additionally, the underwriters will be entitled to a deferred underwriting discount of 2.5% of the gross proceeds of the IPO held in the Trust Account, or $2,300,000 upon the completion of the Company’s initial Business Combination subject to the terms of the underwriting agreement. Representative Shares On February 18, 2021, the Company issued to Maxim Partners LLC, a designee of Maxim Group LLC 92,000 non-redeemable Class A ordinary shares (the “representative shares”). The Company estimated the fair value of the stock to be $920 based upon the price of the founder shares issued to the Sponsor. The representative shares were treated as underwriters’ compensation and charged directly to shareholders’ equity. Maxim Partners LLC has agreed not to transfer, assign or sell any such shares until the completion of the initial Business Combination. In addition, Maxim Partners LLC has agreed (i) to waive its redemption rights with respect to such shares in connection with the completion of the initial Business Combination and (ii) to waive its rights to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete the initial Business Combination within 24 months from the closing of the IPO.

Derivative Liability

Derivative Liability	9 Months Ended
Derivative Liability	Sep. 30, 2021
Derivative Liability.
Derivative Liability	Note 8 — Derivative Liability The Company has outstanding warrants to purchase an aggregate of 8,088,888 shares of the Company’s ordinary shares issued in connection with the Initial Public Offering and the Private Placement (including warrants issued in connection with the consummation of the Over-allotment). Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as discussed herein. The warrants will become exercisable on the later of 30 days after the completion of the initial Business Combination or 12 months from the closing of the IPO and will expire five years after the completion of the initial Business Combination, or earlier upon redemption or liquidation. The Company will not be obligated to deliver any Class A ordinary shares pursuant to the exercise of a Redeemable Warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class A ordinary shares underlying the Redeemable Warrants is then effective and a prospectus relating thereto is current. No Redeemable Warrant will be exercisable, and the Company will not be obligated to issue Class A ordinary shares upon exercise of a warrant unless Class A ordinary shares issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the Redeemable Warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a Redeemable Warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any Redeemable Warrant. In the event that a registration statement is not effective for the exercised Redeemable Warrants, the purchaser of a Unit containing such Redeemable Warrant will have paid the full purchase price for the Unit solely for the Class A ordinary share underlying such Unit. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any founder shares held by the Sponsor or its affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the completion of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company completes the initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price and the $10.00 per share redemption trigger price described below under the heading “Redemption of Redeemable Warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of 100% of the Market Value and the Newly Issued Price. The Forward Purchase Warrants will have the same exercise price as the Redeemable Warrants and be subject to the same price adjustments described above. If the Company’s Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Redeemable Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elect, the Company will not be required to file or maintain in effect a registration statement, but the Company will be required to use commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60 th an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (defined below) less the exercise price of the warrants by (y) the fair market value and (B) 0.3611 per Redeemable Warrant. The “fair market value” as used in this paragraph shall mean the average of the daily volume-weighted average trading prices of the Class A ordinary shares during the 10 consecutive trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00 . Once the warrants become exercisable, the Company may call the Redeemable Warrants (and the Forward Purchase Warrants) for redemption: ● in whole and not in part; ● at a price of $0.01 per warrant; ● upon a minimum of 30 days ’ prior written notice of redemption to each warrant holder, provided that holders will be able to exercise their warrants prior to the time of redemption and, at the Company’ election, any such exercise may be required to be on a cashless basis; and ● if, and only if, the daily volume-weighted average price of the Class A ordinary shares equals or exceeds $18.00 per share for any 20 trading days within a 30-trading-day period ending three trading days before the Company sends the notice of redemption to the warrant holders. Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00 . ● in whole and not in part; ● at $0.10 per warrant upon a minimum of 30 days ’ prior written notice of redemption; provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table described in the prospectus, based on the redemption date and the “fair market value” of the Company’s Class A ordinary shares; and ● if, and only if, the daily volume-weighted average price of the Company’s Class A ordinary shares equals or exceeds $10.00 per public share for any 20 trading days within the 30-trading-day period ending three trading days before the Company sends the notice of redemption to the warrant holders. The warrant agreement contains an Alternative Issuance provision that if less than 70% of the consideration receivable by the holders of the ordinary shares in the Business Combination is payable in the form of common equity in the successor entity, and if the holders of the warrants properly exercises the warrants within thirty days following the public disclosure of the consummation of Business Combination by the Company, the warrant price shall be reduced by an amount equal to the difference (but in no event less than zero) of (i) the warrant price in effect prior to such reduction minus (ii) (A) the Per Share Consideration (as defined below) minus (B) the Black-Scholes Warrant Value (as defined below). The “Black-Scholes Warrant Value” means the value of a Warrant immediately prior to the consummation of the Business Combination based on the Black-Scholes Warrant Model for a Capped American Call on Bloomberg Financial Markets. “Per Share Consideration” means (i) if the consideration paid to holders of the ordinary shares consists exclusively of cash, the amount of such cash per ordinary shares, and (ii) in all other cases, the volume weighted average price of the ordinary shares as reported during the ten-trading day period ending on the trading day prior to the effective date of the Business Combination. The Company believes that the adjustments to the exercise price of the warrants is based on a variable that is not an input to the fair value of a “fixed-for-fixed” option as defined under FASB ASC Topic No. 815 – 40, and thus the warrants are not eligible for an exception from derivative accounting. The accounting treatment of derivative financial instruments requires that the Company record a derivative asset or liability upon the closing of IPO. Accordingly, the Company has classified each warrant as a liability at its fair value and the warrants were allocated a portion of the proceeds from the issuance of the Units equal to its fair value determined by the Monte Carlo simulation and Black-Scholes Option Pricing Model. This liability is subject to re-measurement at each balance sheet date. With each such re-measurement, the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations. The Company will reassess the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification. As such, the Company recorded $10,851,878 of warrant liabilities upon issuance as of February 18, 2021. For the six months ended June 30, 2021 and the three months ended September 30, 2021, the Company recorded a change in the fair value of the warrant liabilities as a decrease in the amount of $2,639,529 and a decrease in the amount of $2,425,258 on the statement of operations, respectively, resulting in warrant liabilities of $5,787,091 as of September 30, 2021 on the balance sheet. The change in fair value of the warrant liabilities is summarized as follows: Warrant liabilities at February 18, 2021 $ 10,851,878 Change in fair value of warrant liabilities (2,639,529) Warrant liabilities at June 30, 2021 $ 8,212,349 Change in fair value of warrant liabilities (2,425,258) Warrant liabilities at September 30, 2021 $ 5,787,091

Shareholders' Equity (Deficit)

Shareholders' Equity (Deficit)	9 Months Ended
Shareholders' Equity (Deficit)	Sep. 30, 2021
Shareholders' Equity (Deficit)
Shareholders' Equity (Deficit)	Note 9 — Shareholders’ Equity (Deficit) Preference Shares Class A Ordinary Shares issued outstanding Class B Ordinary Shares The Company’s Sponsor and management team have agreed not to transfer, assign or sell any of their founder shares until the earliest of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the public shareholders having the right to exchange their ordinary shares for cash, securities or other property. The founder shares will automatically convert into Class A ordinary shares on the first business day following the consummation of the initial Business Combination at a ratio such that the number of Class A ordinary shares issuable upon conversion of all founder shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the IPO, plus (ii) the sum of the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination (including the Forward Purchase Shares), excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any private placement warrants issued to the Sponsor, members of the Company’s management team or any of their affiliates upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one to one. The holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders except as required by law.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2021
Fair Value Measurements
Fair Value Measurements	Note 10 — Fair Value Measurements The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at September 30, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Quoted Prices In Significant Other Significant Other Active Markets Observable Inputs Unobservable Inputs September 30, 2021 (Level 1) (Level 2) (Level 3) Assets: U.S. Money Market held in Trust Account $ 92,007,046 $ 92,007,046 $ — $ — Derivative asset - forward purchase agreement 9,406 — — 9,406 $ 92,016,452 $ 92,007,046 $ — $ 9,406 Liabilities: Warrant Liability - Public $ 725,778 $ 725,778 $ — $ — Warrant Liability – Private 5,061,313 — — 5,061,313 $ 5,787,091 $ 725,778 $ — $ 5,061,313 The estimated fair value of the warrant liability for the private warrants and the derivate asset – forward purchase agreement is determined using Level 3 inputs. Inherent in a binomial options pricing model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares based on historical volatility that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero. The estimated fair value of the derivate asset or liability for the forward purchase agreement is determined using several of the Level 3 inputs used in the valuation of the warrant liability. The following table provides quantitative information regarding Level 3 fair value measurements as of September 30, 2021 : Sept 30, 2021 Exercise price $ 11.5 Share price $ 9.75 Volatility 10 % Expected life 0.69 Risk-free rate 1.10 % Dividend yield — % Transfers to/from Levels 1, 2 and 3 are recognized at the beginning of the reporting period. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement in April 2021 when the Public Warrants were separately listed and traded amounted to approximately $891,000.

Subsequent Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2021
Subsequent Events
Subsequent Events	Note 11 — Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than the restatement discussed in Note 2, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2021
Significant Accounting Policies
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by US GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included Annual Report on Form 10-K filed by the Company with the SEC on March 31, 2021.
Emerging Growth Company Status	Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available and, accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents in its operating account as of September 30, 2021 and December 31, 2020.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of September 30, 2021, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Warrant Liabilities and Derivate Assets - Forward Purchase Agreement	Warrant Liabilities and Derivative Assets - Forward Purchase Agreement The Company accounts for the Warrants and its Forward Purchase Agreement (“FPA”) as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the Warrants and FPA and the applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the Warrants and FPA are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the Warrants and FPA are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance of the Warrants and execution of the FPA and as of each subsequent quarterly period end date while the Warrants and FPA are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, such warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, such warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability-classified warrants are recognized as a non-cash gain or loss on the statements of operations. The Company accounts for the Warrants and FPA in accordance with ASC 815-40 under which the Warrants and FPA do not meet the criteria for equity classification and must be recorded as derivatives. The fair value of the Public Warrants has been estimated using its quoted market price as of September 30, 2021. The fair value of the Private Placement Warrants has been estimated using the modified Black-Scholes-Merton model. The fair value of the FPA has been estimated using an adjusted net assets method. See Note 10 for further discussion of the fair value measurement. The Company evaluated the Public Warrants, contingent rights, Private Placement Warrants and FPA (as defined in Note 8) in accordance with ASC 815-40, “Derivatives and Hedging — Contracts in Entity’s Own Equity”, and concluded that a provision in the Warrant Agreement related to certain tender or exchange offers precludes the Warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as derivative liabilities on the Condensed Balance Sheet and measured at fair value at inception (on the date of the IPO) and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in the Condensed Statement of Operations in the period of change.
Offering Costs Associated with the Initial Public Offering	Offering Costs Associated with the Initial Public Offering The Company complies with the requirements of the ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. The Company allocates the offering costs between ordinary share and warrants using a relative fair value method, pursuant to which the offering costs allocated to the public warrants will be expensed immediately. Accordingly, as of September 30, 2021, allocated offering costs in the aggregate of $205,898 have been charged to operations.
Class A Ordinary Shares Subject to Possible Redemption	Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, Class A ordinary shares is classified as shareholders’ equity. Most of the Company’s Class A ordinary shares feature certain redemption rights that is considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, 9,200,000 Class A ordinary shares subject to possible redemption were presented as temporary equity, outside of the shareholders’ equity section of the Company’s unaudited condensed balance sheet.
Income Taxes	Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes (“ASC 740”). ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for the financial statements’ recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. The Company’s management does not expect the total amount of unrecognized tax benefits will materially change over the next twelve months. The provision for income taxes was deemed to be de minimis for the three and nine months ended September 30, 2021.
Net Income (Loss) Per Ordinary Share	Net Income (Loss) Per Ordinary Share Net income (loss) per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the IPO and Private Placement to purchase an aggregate of 8,088,889 shares of the Company’s Class A Ordinary Shares in the calculation of diluted income (loss) per share, since their exercise is contingent. Accretion associated with the redeemable shares of Class A ordinary share is excluded from earnings per share as the redemption value approximates fair value. As a result, diluted income per ordinary share is the same as basic income per ordinary share. For the three months ended September 30, 2021 Class A C lass B Allocation of net income including ordinary shares subject to possible redemption $ 1,807,501 $ 451,875 Weighted Average Ordinary Shares outstanding 9,292,000 2,323,000 Basic and Diluted net income per share $ 0.19 $ 0.19 For the nine months ended September 30, 2021 Class A C lass B Allocation of net income including ordinary shares subject to possible redemption $ 1,668,307 $ 494,405 Weighted Average Ordinary Shares outstanding 7,658,242 2,269,529 Basic and Diluted net income per share $ 0.22 $ 0.22
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company follows the guidance in ASC 820, “Fair Value Measurement,” for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment. Level 2 — Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means. Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement. As of September 30, 2021 and December 31, 2020, the carrying values of cash, prepaid expenses, and current liabilities approximate their fair values due to the short-term nature of the instruments. See Note 10 for additional information on assets and liabilities measured at fair value.
Recent Accounting Standards	Recent Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

Restatement of Previously Iss_2

Restatement of Previously Issued Financial Statements (Tables)	9 Months Ended
	Sep. 30, 2021
Restatement of Previously Issued Financial Statements
Schedule of impact of the restatement on the Company's financial statements	As As Reported Adjustment Restated Balance Sheet as of March 31, 2021 (per Form 10-Q filed on May 24, 2021) Ordinary shares subject to possible redemption ($) $ 79,905,570 $ 12,094,430 $ 92,000,000 Shareholders’ equity (deficit) Class A ordinary shares, $0.0001 par value 130 (121) 9 Additional paid-in capital 3,559,352 (3,559,352) — Accumulated Deficit 1,440,290 (8,534,957) (7,094,667) Total shareholders’ equity (deficit) $ 5,000,004 $ (12,094,430) $ (7,094,426) Shares subject to possible redemption 7,990,557 1,209,443 9,200,000 Statement of Operations for the Three Months Ended March 31, 2021 (per Form 10-Q filed on May 24, 2021) Weighted average shares outstanding, Redeemable Class A ordinary shares 9,292,000 (5,058,978) 4,233,022 Basic and diluted net income per share, Redeemable Class A ordinary shares $ — $ 0.23 $ 0.23 Weighted average shares outstanding, Non-redeemable Class A and Class B ordinary shares 2,158,033 — 2,158,033 Basic and diluted net income per shares, Non-redeemable Class A and Class B ordinary shares $ 0.67 $ (0.44) $ 0.23 Statement of Changes in Shareholders’ Equity as of March 31, 2021 (per Form 10-Q filed on May 24, 2021) Sale of 9,200,000 Units on February 18, 2021 through IPO, including over-allotment, net of fair value of warrant liability and offering costs $ 83,439,364 $ (83,439,364) $ — Change in Class A ordinary shares subject to possible redemption (79,905,570) 79,905,570 — Remeasurement of Class A ordinary shares subject to possible redemption against additional paid-in capital and accumulated deficit — (8,560,636) (8,560,636) Statement of Cash Flows as of March 31, 2021 (per Form 10-Q filed on May 24, 2021) Initial value of shares subject to possible redemption $ 75,523,530 $ 16,476,470 $ 92,000,000 Change in value of Class A ordinary shares subject to possible redemption $ 4,382,040 $ (4,382,040) $ — Balance Sheet as of June 30, 2021 (per Form 10-Q filed on August 5, 2021) Ordinary shares subject to possible redemption ($) $ 78,362,550 $ 13,637,450 $ 92,000,000 Shareholders’ equity (deficit) Class A ordinary shares, $0.0001 par value 146 (137) 9 Additional paid-in capitaT 5,102,357 (5,102,357) — Accumulated Deficit (102,731) (8,534,957) (8,637,688) Total shareholders’ equity (deficit) $ 5,000,004 $ (13,637,451) $ (8,637,447) Shares subject to possible redemption 7,836,255 1,363,745 9,200,000 Statement of Operations for the Three Months Ended June 30, 2021 (per Form 10-Q filed on August 5, 2021) Weighted average shares outstanding, Redeemable Class A ordinary shares 9,292,000 — 9,292,000 Basic and diluted net income per share, Redeemable Class A ordinary shares $ — $ (0.13) $ (0.13) Weighted average shares outstanding, Non-redeemable Class A and Class B ordinary shares 2,323,000 — 2,323,000 Basic and diluted net income per shares, Non-redeemable Class A and Class B ordinary shares $ (0.05) $ (0.08) $ (0.13) Statement of Operations for the Six Months Ended June 30, 2021 (per Form 10-Q filed on August 5, 2021) Weighted average shares outstanding, Redeemable Class A ordinary shares 9,292,000 (2,515,514) 6,776,486 Basic and diluted net income per share, Redeemable Class A ordinary shares $ — $ (0.01) $ (0.01) Weighted average shares outstanding, Non-redeemable Class A and Class B ordinary shares 2,242,000 (1,028) 2,240,972 Basic and diluted net income per shares, Non-redeemable Class A and Class B ordinary shares $ (0.67) $ 0.66 $ (0.01) Statement of Changes in Shareholders’ Equity as of June 30, 2021 (per Form 10-Q filed on August 5, 2021) Remeasurement in Class A ordinary shares subject to possible redemption $ 1,543,021 $ (1,543,021) $ — Statement of Cash Flows as of June 30, 2021 (per Form 10-Q filed on August 5, 2021) Initial value of shares subject to possible redemption $ 75,523,535 $ 16,476,465 $ 92,000,000 Change in value of Class A ordinary shares subject to possible redemption $ 2,839,015 $ (2,839,015) $ —

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	9 Months Ended
Significant Accounting Policies (Tables)	Sep. 30, 2021
Significant Accounting Policies
Schedule of basic and diluted net income (loss) per ordinary share	For the three months ended September 30, 2021 Class A C lass B Allocation of net income including ordinary shares subject to possible redemption $ 1,807,501 $ 451,875 Weighted Average Ordinary Shares outstanding 9,292,000 2,323,000 Basic and Diluted net income per share $ 0.19 $ 0.19 For the nine months ended September 30, 2021 Class A C lass B Allocation of net income including ordinary shares subject to possible redemption $ 1,668,307 $ 494,405 Weighted Average Ordinary Shares outstanding 7,658,242 2,269,529 Basic and Diluted net income per share $ 0.22 $ 0.22

Initial Public Offering ("IPO_2

Initial Public Offering ("IPO") (Tables)	9 Months Ended
Initial Public Offering ("IPO") (Tables)	Sep. 30, 2021
Initial Public Offering ("IPO")
Schedule of redeemable ordinary shares subject to possible redemption reflected on the balance sheet	As of September 30, 2021, the redeemable Class A ordinary shares reflected on the balance sheet are reconciled in the following table: Gross proceeds from public issuance $ 92,000,000 Less: Proceeds allocated to public warrants (4,089,353) Class A ordinary shares issuance costs (4,471,283) Plus: Accretion of carrying value to redemption value 8,560,636 Contingently redeemable Class A ordinary share $ 92,000,000

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
Related Party Transactions (Tables)	Sep. 30, 2021
Related Party Transactions
Schedule of Derivative Instruments	Derivate liability - forward purchase agreement at February 18, 2021 $ (521,597) Change in fair value of derivate instrument related to forward purchase agreement 529,744 Derivative asset - forward purchase agreement at June 30, 2021 $ 8,147 Change in fair value of derivate instrument related to forward purchase agreement 1,259 Derivative asset - forward purchase agreement at September 30, 2021 $ 9,406

Derivative Liability (Tables)

Derivative Liability (Tables)	9 Months Ended
Derivative Liability (Tables)	Sep. 30, 2021
Derivative Liability.
Schedule of change in the fair value of the warrant liabilities	The change in fair value of the warrant liabilities is summarized as follows: Warrant liabilities at February 18, 2021 $ 10,851,878 Change in fair value of warrant liabilities (2,639,529) Warrant liabilities at June 30, 2021 $ 8,212,349 Change in fair value of warrant liabilities (2,425,258) Warrant liabilities at September 30, 2021 $ 5,787,091

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2021
Fair Value Measurements
Schedule of company's assets that are measured at fair value on a recurring basis	The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at September 30, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Quoted Prices In Significant Other Significant Other Active Markets Observable Inputs Unobservable Inputs September 30, 2021 (Level 1) (Level 2) (Level 3) Assets: U.S. Money Market held in Trust Account $ 92,007,046 $ 92,007,046 $ — $ — Derivative asset - forward purchase agreement 9,406 — — 9,406 $ 92,016,452 $ 92,007,046 $ — $ 9,406 Liabilities: Warrant Liability - Public $ 725,778 $ 725,778 $ — $ — Warrant Liability – Private 5,061,313 — — 5,061,313 $ 5,787,091 $ 725,778 $ — $ 5,061,313
Schedule of quantitative information regarding Level 3 fair value measurements inputs	Sept 30, 2021 Exercise price $ 11.5 Share price $ 9.75 Volatility 10 % Expected life 0.69 Risk-free rate 1.10 % Dividend yield — %

Organization and Business Ope_2

Organization and Business Operations (Details)	Mar. 31, 2021shares	Feb. 18, 2021USD ($)$ / sharesshares	Feb. 12, 2021USD ($)	Nov. 26, 2020	Mar. 31, 2021USD ($)	Sep. 30, 2021USD ($)$ / sharesshares
Subsidiary, Sale of Stock [Line Items]
Sale of Units, including over-allotment, net of fair value of warrant liability and offering costs (in shares) \| shares	9,200,000	9,200,000
Purchase price, per unit \| $ / shares						$ 10
Proceeds from issuance initial public offering						$ 92,000,000
Transaction Costs			$ 4,677,181
Underwriting fees			1,840,000
Deferred underwriting fee payable			2,300,000
Issuance of representative shares			920		$ 920
Other offering costs			$ 537,181
Condition for future business combination number of businesses minimum				1
Payments for investment of cash in Trust Account						$ 92,000,000
Sponsor \| Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares) \| shares						3,642,222
Maxim \| Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares) \| shares						1,380,000
Initial Public Offering
Subsidiary, Sale of Stock [Line Items]
Purchase price, per unit \| $ / shares		$ 10
Non-redeemable Class A ordinary shares designated \| shares						92,000
Common Stock Value Designated						$ 920
Payments for investment of cash in Trust Account		$ 92,000,000
Condition for future business combination threshold Percentage Ownership		100
Months to complete acquisition		24 months
Redemption period upon closure		185 days
Initial Public Offering \| Warrants
Subsidiary, Sale of Stock [Line Items]
Price of warrant \| $ / shares		$ 11.50
Private Placement. \| Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares) \| shares						5,022,222
Price of warrant \| $ / shares						$ 0.90
Proceeds from private placement						$ 4,520,000
Private Placement. \| Sponsor
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares) \| shares						3,642,222
Private Placement. \| Maxim
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares) \| shares						1,380,000
Over-allotment option
Subsidiary, Sale of Stock [Line Items]
Sale of Units, including over-allotment, net of fair value of warrant liability and offering costs (in shares) \| shares		1,200,000
Purchase price, per unit \| $ / shares		$ 10
Proceeds from issuance initial public offering		$ 92,000,000

Restatement of Previously Iss_3

Restatement of Previously Issued Financial Statements (Details)	Sep. 30, 2021USD ($)$ / shares
Restatement of Previously Issued Financial Statements
Condition for future business combination threshold Net Tangible Assets \| $	$ 5,000,001
Purchase price, per unit \| $ / shares	$ 10

Restatement of Previously Iss_4

Restatement of Previously Issued Financial Statements - Balance Sheet (Details) - USD ($)	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary share subject to possible redemption	$ 92,000,000	$ 92,000,000	$ 92,000,000
Additional Paid in Capital				$ 24,768
Accumulated Deficit	(6,378,312)	(8,637,688)	(7,094,667)	(6,068)
Total shareholders' equity (deficit)	(6,378,071)	$ (8,637,447)	$ (7,094,426)	18,932
Shares subject to possible redemption		9,200,000	9,200,000
As Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary share subject to possible redemption		$ 78,362,550	$ 79,905,570
Additional Paid in Capital		5,102,357	3,559,352
Accumulated Deficit		(102,731)	1,440,290
Total shareholders' equity (deficit)		$ 5,000,004	$ 5,000,004
Shares subject to possible redemption		7,836,255	7,990,557
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary share subject to possible redemption		$ 13,637,450	$ 12,094,430
Additional Paid in Capital		(5,102,357)	(3,559,352)
Accumulated Deficit		(8,534,957)	(8,534,957)
Total shareholders' equity (deficit)		$ (13,637,451)	$ (12,094,430)
Shares subject to possible redemption		1,363,745	1,209,443
Class A ordinary shares
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares	9	$ 9	$ 9
Class A ordinary shares \| As Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares		146	130
Class A ordinary shares \| Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares		$ (137)	$ (121)
Class B ordinary shares
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Ordinary shares	$ 232			$ 232

Restatement of Previously Iss_5

Restatement of Previously Issued Financial Statements - Statements of Operations (Details) - $ / shares	Mar. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Jun. 30, 2021	Sep. 30, 2021
Class A ordinary shares
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income per ordinary share (Basic)		$ 0.19			$ 0.22
Weighted average shares outstanding (basic)		9,292,000			7,658,242
Net income per ordinary share (Diluted)		$ 0.19			$ 0.22
Weighted average shares outstanding (Diluted)		9,292,000			7,658,242
Common Class Subject To Redemption
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income per ordinary share (Basic)	$ 0.23		$ (0.13)	$ (0.01)
Weighted average shares outstanding (basic)	4,233,022		9,292,000	6,776,486
Net income per ordinary share (Diluted)	$ 0.23		$ (0.13)	$ (0.01)
Weighted average shares outstanding (Diluted)	4,233,022		9,292,000	6,776,486
Common Class Not Subject To Redemption
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income per ordinary share (Basic)	$ 0.23		$ (0.13)	$ (0.01)
Weighted average shares outstanding (basic)	2,158,033		2,323,000	2,240,972
Net income per ordinary share (Diluted)	$ 0.23		$ (0.13)	$ (0.01)
Weighted average shares outstanding (Diluted)	2,158,033		2,323,000	2,240,972
Class B ordinary shares
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income per ordinary share (Basic)		$ 0.19			$ 0.22
Weighted average shares outstanding (basic)		2,323,000			2,269,529
Net income per ordinary share (Diluted)		$ 0.19			$ 0.22
Weighted average shares outstanding (Diluted)		2,323,000			2,269,529
As Reported \| Common Class Subject To Redemption
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Weighted average shares outstanding (basic)	9,292,000		9,292,000	9,292,000
Weighted average shares outstanding (Diluted)	9,292,000		9,292,000	9,292,000
As Reported \| Common Class Not Subject To Redemption
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income per ordinary share (Basic)	$ 0.67		$ (0.05)	$ (0.67)
Weighted average shares outstanding (basic)	2,158,033		2,323,000	2,242,000
Net income per ordinary share (Diluted)	$ 0.67		$ (0.05)	$ (0.67)
Weighted average shares outstanding (Diluted)	2,158,033		2,323,000	2,242,000
Adjustment \| Common Class Subject To Redemption
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income per ordinary share (Basic)	$ 0.23		$ (0.13)	$ (0.01)
Weighted average shares outstanding (basic)	(5,058,978)			(2,515,514)
Net income per ordinary share (Diluted)	$ 0.23		(0.13)	$ (0.01)
Weighted average shares outstanding (Diluted)	(5,058,978)			(2,515,514)
Adjustment \| Common Class Not Subject To Redemption
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income per ordinary share (Basic)	$ (0.44)		(0.08)	$ 0.66
Weighted average shares outstanding (basic)				(1,028)
Net income per ordinary share (Diluted)	$ (0.44)		$ (0.08)	$ 0.66
Weighted average shares outstanding (Diluted)				(1,028)

Restatement of Previously Iss_6

Restatement of Previously Issued Financial Statements - Shareholders' Equity (Details) - USD ($)	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Common stock subject to possible redemption			$ 8,560,636
As Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Sale of 9,200,000 Units on February 18, 2021 through IPO, including over-allotment, net of fair value of warrant liability and offering costs		$ 83,439,364
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Sale of 9,200,000 Units on February 18, 2021 through IPO, including over-allotment, net of fair value of warrant liability and offering costs		(83,439,364)
Class A ordinary shares \| As Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Common stock subject to possible redemption		(79,905,570)
Class A ordinary shares \| Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Common stock subject to possible redemption		79,905,570
Common Class Subject To Redemption
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Remeasurement of Class A ordinary shares subject to possible redemption against additional paid-in capital and accumulated deficit		(8,560,636)
Common Class Subject To Redemption \| As Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Common stock subject to possible redemption	$ 1,543,021
Common Class Subject To Redemption \| Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Common stock subject to possible redemption	$ (1,543,021)
Remeasurement of Class A ordinary shares subject to possible redemption against additional paid-in capital and accumulated deficit		$ (8,560,636)

Restatement of Previously Iss_7

Restatement of Previously Issued Financial Statements - Statements of Cashflows (Details) - USD ($)	Jun. 30, 2021	Mar. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Initial value of shares subject to possible redemption	$ 92,000,000	$ 92,000,000
As Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Initial value of shares subject to possible redemption	75,523,535	75,523,530
Chang in value of Class A ordinary shares subject to possible redemption	2,839,015
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Initial value of shares subject to possible redemption	16,476,465	16,476,470
Chang in value of Class A ordinary shares subject to possible redemption	$ (2,839,015)
Common Class Subject To Redemption \| As Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Chang in value of Class A ordinary shares subject to possible redemption		4,382,040
Common Class Subject To Redemption \| Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Chang in value of Class A ordinary shares subject to possible redemption		$ (4,382,040)

Restatement of Previously Iss_8

Restatement of Previously Issued Financial Statements - Additional Information (Details) - $ / shares	Mar. 31, 2021	Feb. 18, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Sale of Units, including over-allotment, net of fair value of warrant liability and offering costs (in shares)	9,200,000	9,200,000
Class A ordinary shares
Ordinary shares, par value, (per share)	$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001

Significant Accounting Polici_4

Significant Accounting Policies (Details) - USD ($)	9 Months Ended
Significant Accounting Policies (Details) - USD ($)	Sep. 30, 2021	Feb. 18, 2021	Dec. 31, 2020	Dec. 06, 2020
Aggregate cash offering costs	$ 205,898
Federal Depository Insurance Coverage	250,000
Unrecognized tax benefits	0		$ 0
Unrecognized tax benefits accrued for interest and penalties	$ 0
Class B ordinary shares
Ordinary shares, shares subject to possible redemption, issued (in shares)	2,323,000	303,000		303,000
Class A ordinary shares
Ordinary shares, shares subject to possible redemption, issued (in shares)	9,200,000
Anti-dilutive securities attributable to warrants (in shares)	8,088,889

Significant Accounting Polici_5

Significant Accounting Policies - Calculation of basic and diluted net income (loss) per ordinary share (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Class A ordinary shares
Allocation of net income including ordinary shares subject to possible redemption	$ 1,807,501	$ 1,668,307
Class B ordinary shares
Allocation of net income including ordinary shares subject to possible redemption	$ 451,875	$ 494,405

Initial Public Offering ("IPO_3

Initial Public Offering ("IPO") (Details) - $ / shares	Mar. 31, 2021	Feb. 18, 2021	Sep. 30, 2021
Subsidiary, Sale of Stock [Line Items]
Number of units sold	9,200,000	9,200,000
Purchase price, per unit			$ 10
Initial Public Offering
Subsidiary, Sale of Stock [Line Items]
Purchase price, per unit		$ 10
Initial Public Offering \| Public Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants in a unit		0.5
Number of shares issuable per warrant		0.2
Initial Public Offering \| Class A ordinary shares
Subsidiary, Sale of Stock [Line Items]
Number of units sold			9,200,000
Over-allotment option
Subsidiary, Sale of Stock [Line Items]
Number of units sold		1,200,000
Purchase price, per unit		$ 10
Over-allotment option \| Class A ordinary shares
Subsidiary, Sale of Stock [Line Items]
Number of units sold		1,200,000

Initial Public Offering ("IPO_4

Initial Public Offering ("IPO") - Ordinary share reflected on the balance sheet (Details)	9 Months Ended
	Sep. 30, 2021USD ($)
Initial Public Offering ("IPO")
Proceeds allocated to public warrants	$ (4,089,353)
Class A ordinary shares issuance costs	(4,471,283)
Accretion of carrying value to redemption value	8,560,636
Contingently redeemable Class A ordinary share	$ 92,000,000

Private Placement (Details)

Private Placement (Details)	9 Months Ended
Private Placement (Details)	Sep. 30, 2021USD ($)$ / sharesshares
Sponsor \| Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued	3,642,222
Maxim \| Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued	1,380,000
Private Placement. \| Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued	5,022,222
Price of warrants \| $ / shares	$ 0.90
Aggregate purchase price \| $	$ 4,520,000
Number of shares per warrant	1
Exercise price of warrant \| $ / shares	$ 11.50
Private Placement. \| Sponsor
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued	3,642,222
Private Placement. \| Maxim
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued	1,380,000

Related Party Transactions - Fo

Related Party Transactions - Founder Shares (Details)	Feb. 18, 2021D$ / sharesshares	Sep. 30, 2021USD ($)Dshares
Related Party Transaction [Line Items]
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination \| D		20
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination \| D		30
Founder shares \| Sponsor \| Class B ordinary shares
Related Party Transaction [Line Items]
Number of shares issued \| shares		2,323,000
Aggregate purchase price \| $		$ 25,000
Share dividend \| shares		0.01
Aggregate number of shares owned \| shares		303,000
Shares subject to forfeiture \| shares	303,000
Restrictions on transfer period of time after business combination completion	1 year
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) \| $ / shares	$ 12
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination \| D	20
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination \| D	30
Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences	150 days

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($)	Feb. 18, 2021	Sep. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Sep. 30, 2021	Dec. 07, 2020
Related Party Transaction [Line Items]
Working capital loans					$ 2,000,000
Private placement warrant					$ 0.90
Due to related party		$ 25,714			$ 25,714
Derivative liability current	$ 521,597
Fair Value Adjustment of Warrants		(2,426,517)			(2,831,668)
Forward purchase agreement
Related Party Transaction [Line Items]
Fair Value Adjustment of Warrants		1,259	$ 529,744	$ 529,744
Derivative Asset	(521,597)	9,406		$ 8,147	9,406
Promissory Note with Related Party
Related Party Transaction [Line Items]
Maximum borrowing capacity of related party promissory note						$ 300,000
Outstanding balance of related party note		0			0
Repayment of promissory note - related party	300,000
Administrative Support Agreement
Related Party Transaction [Line Items]
Due to Affiliate		25,714			25,714
Expenses per month	$ 10,000
Expenses incurred and paid		55,714
Administrative service fee					30,000
Related Party Loans
Related Party Transaction [Line Items]
Loan conversion agreement warrant		$ 16,000,000			$ 16,000,000
Purchase units					1,600,000
Related Party Loans \| Working capital loans warrant
Related Party Transaction [Line Items]
Price of warrant		$ 10			$ 10

Related Party Transactions - Sc

Related Party Transactions - Schedule Of Derivative Instruments (Details) - USD ($)	3 Months Ended		4 Months Ended	9 Months Ended
	Sep. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Sep. 30, 2021
Subsidiary, Sale of Stock [Line Items]
Change in fair value of derivate instrument related to forward purchase agreement	$ (2,426,517)			$ (2,831,668)
Forward purchase agreement
Subsidiary, Sale of Stock [Line Items]
Derivate assets (liability) - forward purchase agreement	8,147		$ (521,597)
Change in fair value of derivate instrument related to forward purchase agreement	1,259	$ 529,744	529,744
Derivative asset - forward purchase agreement	$ 9,406		$ 8,147	$ 9,406

Commitments and Contingencies (

Commitments and Contingencies (Details)	Feb. 18, 2021USD ($)shares	Sep. 30, 2021USD ($)	Oct. 31, 2020item
Commitments and Contingencies.
Maximum number of demands for registration of securities \| item			3
Underwriting cash discount per unit		2.00%
Underwriter cash discount		$ 1,840,000
Underwriting Discount		2.50%
Aggregate underwriter cash discount		$ 2,300,000
Non-redeemable Class A ordinary shares \| shares	92,000
Estimated the fair value	$ 920

Derivative Liability (Details)

Derivative Liability (Details) - USD ($)	Mar. 31, 2021	Feb. 18, 2021	Sep. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2021	Sep. 30, 2021	Dec. 31, 2020
Subsidiary, Sale of Stock [Line Items]
Number of units sold	9,200,000	9,200,000
Purchase price, per unit			$ 10				$ 10
Exercisable on the later							5 years
Public warrants expire							30 days
Weighted average trading days							20 days
Newly issued price							$ 115
Ordinary share adjusted							$ 18
Warrant liability		$ 10,851,878	$ 5,787,091		$ 8,212,349	$ 8,212,349	$ 5,787,091
Change in fair value of warrant liabilities			2,425,258		2,639,529	2,639,529
Derivative liability current		521,597
Fair Value Adjustment of Warrants			(2,426,517)				$ (2,831,668)
Minimum
Subsidiary, Sale of Stock [Line Items]
Weighted average trading days							30 days
Warrant price							$ 0.10
Forward purchase agreement
Subsidiary, Sale of Stock [Line Items]
Fair Value Adjustment of Warrants			1,259	$ 529,744	529,744
Derivative Asset		$ (521,597)	$ 9,406		$ 8,147	$ 8,147	$ 9,406
Class A ordinary shares
Subsidiary, Sale of Stock [Line Items]
Common shares, issued (in shares)			92,000				92,000	0
Exercise price of warrants			$ 11.50				$ 11.50
Effective issue price							$ 9.20
Total equity proceeds							60.00%
Weighted average trading days							20 days
Higher of the Market Value							180.00%
Newly issued price							$ 18
Ordinary share equals or exceeds							18
Redemption trigger price							10
Ordinary share adjusted							$ 10
Market value and the newly issued price							100.00%
Redeemable Warrant							$ 0.3611
Ordinary share exercisable							18
Warrant price							0.01
Public share							10
Class A ordinary shares \| Public Warrants
Subsidiary, Sale of Stock [Line Items]
Exercise price of warrants			$ 9.20				$ 9.20
Initial Public Offering
Subsidiary, Sale of Stock [Line Items]
Purchase price, per unit		$ 10
Public warrants expire							12 months
Initial Public Offering \| Public Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants in a unit		0.5
Number of shares issuable per warrant		0.2
Initial Public Offering \| Class A ordinary shares
Subsidiary, Sale of Stock [Line Items]
Number of units sold							9,200,000
Over-allotment option
Subsidiary, Sale of Stock [Line Items]
Number of units sold		1,200,000
Purchase price, per unit		$ 10
Over-allotment option \| Class A ordinary shares
Subsidiary, Sale of Stock [Line Items]
Number of units sold		1,200,000
Initial Public Offering And Private Placement
Subsidiary, Sale of Stock [Line Items]
Common shares, issued (in shares)			8,088,888				8,088,888

Derivative Liability - Change i

Derivative Liability - Change in the Fair Value of the Warrant Liabilities (Details) - USD ($)	3 Months Ended	4 Months Ended	6 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Jun. 30, 2021
Derivative Liability.
Warrant liabilities at the beginning	$ 8,212,349	$ 10,851,878
Change in fair value of warrant liabilities	(2,425,258)	(2,639,529)	$ (2,639,529)
Warrant liabilities at the ending	$ 5,787,091	$ 8,212,349	$ 8,212,349

Shareholders' Equity (Deficit)

Shareholders' Equity (Deficit) - Preferred Stock Shares (Details) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Shareholders' Equity (Deficit)
Preferred shares, shares authorized	1,000,000	1,000,000
Preferred stock, par value, (per share)	$ 0.0001	$ 0.0001
Preferred shares, shares issued	0	0
Preferred shares, shares outstanding	0	0

Shareholders' Equity (Deficit_2

Shareholders' Equity (Deficit) - Common Stock Shares (Details) - USD ($)	Dec. 06, 2020	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Feb. 18, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Class A common stock subject to possible redemption, outstanding (in shares)			9,200,000	9,200,000
Class A ordinary shares
Class of Stock [Line Items]
Common shares, shares authorized (in shares)		200,000,000				200,000,000
Common shares, par value (in dollars per share)		$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001
Common shares, issued (in shares)		92,000				0
Common shares, shares outstanding (in shares)		92,000				0
Ordinary shares, shares subject to possible redemption, issued (in shares)		9,200,000
Class A ordinary shares subject to possible redemption
Class of Stock [Line Items]
Common shares, par value (in dollars per share)		$ 10				$ 10
Ordinary shares, shares subject to possible redemption, issued (in shares)		9,200,000				0
Class A common stock subject to possible redemption, outstanding (in shares)		9,200,000				0
Class B ordinary shares
Class of Stock [Line Items]
Common shares, shares authorized (in shares)		20,000,000				20,000,000
Common shares, par value (in dollars per share)	$ 0.01	$ 0.0001				$ 0.0001
Common shares, issued (in shares)		2,323,000				2,323,000
Common shares, shares outstanding (in shares)		2,323,000				2,323,000
Ordinary shares, shares subject to possible redemption, issued (in shares)	303,000	2,323,000			303,000
Sponsor paid	$ 25,000

Shareholders' Equity (Deficit_3

Shareholders' Equity (Deficit) - Additional information (Details)	9 Months Ended
	Sep. 30, 2021D$ / shares
Class of Warrant or Right [Line Items]
Warrant exercise period condition one	1 year
Warrant exercise period condition two	150 days
Redemption price per public warrant (in dollars per share) \| $ / shares	$ 12
Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Trading Days	20
Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Consecutive Trading Days	30
Class B ordinary shares
Class of Warrant or Right [Line Items]
Period of time within which registration statement is expected to become effective	20.00%

Fair Value Measurements (Detail

Fair Value Measurements (Details)	Sep. 30, 2021USD ($)
Assets:
Asset Held In Trust Account	$ 92,016,452
Derivative asset - forward purchase agreement	9,406
Liabilities, Fair Value Disclosure [Abstract]
Warrant liability	5,787,091
Public Warrants
Liabilities, Fair Value Disclosure [Abstract]
Warrant liability	725,778
Private Placement Warrants
Liabilities, Fair Value Disclosure [Abstract]
Warrant liability	5,061,313
U.S. Money Market
Assets:
Asset Held In Trust Account	92,007,046
Level 1
Assets:
Asset Held In Trust Account	92,007,046
Liabilities, Fair Value Disclosure [Abstract]
Warrant liability	725,778
Level 1 \| Public Warrants
Liabilities, Fair Value Disclosure [Abstract]
Warrant liability	725,778
Level 1 \| U.S. Money Market
Assets:
Asset Held In Trust Account	92,007,046
Level 3
Assets:
Asset Held In Trust Account	9,406
Derivative asset - forward purchase agreement	9,406
Liabilities, Fair Value Disclosure [Abstract]
Warrant liability	5,061,313
Level 3 \| Private Placement Warrants
Liabilities, Fair Value Disclosure [Abstract]
Warrant liability	$ 5,061,313

Fair Value Measurements - Level

Fair Value Measurements - Level 3 Fair Value Measurements Inputs (Details)	1 Months Ended
	Apr. 30, 2021USD ($)	Sep. 30, 2021Y
Public Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value of the Public Warrants transferred from a Level 3 \| $	$ 891,000
Exercise price \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input		11.5
Share price \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input		9.75
Volatility \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input		10
Expected life \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input \| Y		0.69
Risk-free rate \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input		1.10
Dividend yield \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input		0